In their first report, they showed that renalase is secreted by the kidney into the blood and is capable of metabolizing catecholamines (dopamine, epinephrine and norepinephrine) 1 . Although the renalase gene expression in human was found highest in the kidney it was also detectable in the heart, skeletal muscle and small intestine. The most striking clinically relevant finding was the identification of a markedly reduced plasma renalase concentration in patients with end-stage renal disease. Interestingly, animal studies demonstrated that the renalase infusion could decrease cardiac contractility, heart rate and blood pressure in rats 1 . Subsequent studies found decreased plasma and tissue levels of renalase in animal models of hypertension and chronic kidney disease 3 . Interestingly, renalase knockout mice were found hypertensive and they showed increased sympathetic tone and elevated levels of plasma and urinary catecholamines in absence of any significant alteration in renal function 4 . Human studies also demonstrated an inverse relationship between plasma renalase level and systolic blood pressure in patients with resistant hypertension 5 . Moreover, a functional mutation in renalase gene has been found to be associated with essential hypertension 6 . Linking the findings obtained so far, it has been
